课题基金 / 基金详情

VALACYCLOVIR THERAPY OF SHINGLES IN IMMUNOCOMPETENT PATIENTS

VALACYCLOVIR THERAPY OF SHINGLES IN IMMUNOCOMPETENT PATIENTS
伐昔洛韦治疗免疫功能正常患者带状疱疹
批准号：
6413652
负责人：
STEPHEN K TYRING
金额：
$27.93万
依托单位：
UNIVERSITY OF TEXAS MED BR GALVESTON
依托单位国家：
美国
项目类别：
财政年份：
2000
资助国家：
美国
项目状态：
已结题
起止时间：
2000-12-01 至 2001-11-30
来源：
https://reporter.nih.gov/project-details/6413652
关键词：
acyclovir adult human (21+) antiviral agents chronic pain clinical chemistry clinical research clinical trial phase I drug adverse effect drug screening /evaluation hematology human subject human therapy evaluation medical complication microorganism disease chemotherapy oral administration prodrugs quality of life self help sensory discrimination shingles

项目摘要

项目成果

STEPHEN K TYRING的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Valacyclovir 1.5 gram BID is safe and effective for treatment of localized herpes zoster in immunocompetent patients 18 years of age and older. This is an open label single center trial to determine the efficacy and safety of valacyclovir 1.5 grams BID for the treatment of uncomplicated herpes zoster in immunocompetent patients 18 years of age and older. The total duration of the study in patients under 50 years of age is 4 weeks. Patients will be evaluated for pain, abnormal sensations, zoster complications, quality of life and resource use. Safety will be assessed by monitoring clinical chemistry and hematology and by reporting adverse experiences (AEs). Chronic zoster-associated pain is markedly more common in patients >50 years old. These patients will be followed for 24 weeks, as most patients on antiviral therapy will cease to experience complication of zoster by week 24.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Genetic Resistance to Oncogenic Human Papillomaviruses
Genetic Resistance to Oncogenic Human Papillomaviruses
ABT 606 VS ACYCLOVIR FOR TREATMENT OF HERPES ZOSTER
STUDY OF ORAL LOBUCAVIR IN PATIENTS WITH RECURRENT GENITAL HERPES